|
| Friday, October 16, 2020 |
|
|
Eisai: Supplementary New Drug Applications for Anti-Epileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures |
| Eisai Co., Ltd. announced today that the supplementary new drug applications for its in-house discovered and developed anti-epileptic drug (AED) Fycompa (generic name: perampanel) as monotherapy for partial-onset seizures and pediatric indication for partial onset seizures in patients with epilepsy 4 years or older have been accepted in China by the National Medical Products Administration. more info >> |
|
| Thursday, October 8, 2020 |
|
|
The University of Tokyo and Eisai Announce Research Collaboration for the Development and Drug Discovery of Targeted Protein Degradation Technology |
| The University of Tokyo and Eisai Co., Ltd. announced today a collaboration aiming for the development and drug discovery of targeted protein degradation technology has been created, with the establishment of a social cooperation program, "Protein Degradation Drug Discovery". more info >> |
|
| Tuesday, October 6, 2020 |
|
|
Eisai: Joint Development Agreement Aiming for Drug Discovery for COVID-19 Utilizing Eritoran and E6011 Concluded |
| In patients with COVID-19 due to the SARS-CoV-2 infection, severe cases such as acute respiratory distress syndrome (ARDS) and subsequent multiple organ failure have been reported. more info >> |
|
| Wednesday, September 30, 2020 |
|
|
Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea |
| Eisai and Seikagaku signed an agreement for the co-development and marketing alliance in China of SI-613 on April 1, 2020. more info >> |
|
| Monday, September 28, 2020 |
|
|
Eisai: Jyseleca (Filgotinib) Approved in Japan for Rheumatoid Arthritis |
| Gilead Japan will hold the marketing authorization of Jyseleca in Japan and will be responsible for the product supply of Jyseleca in Japan, while Eisai will be responsible for product distribution of Jyseleca in Japan in RA. more info >> |
|
| Wednesday, September 23, 2020 |
|
|
Eisai Receives Positive Opinion from EMA's CHMP on Use of Antiepileptic Agent Fycompa in Pediatric Patients |
| The CHMP's positive opinion is to extend the use of Fycompa as an adjunctive therapy for partial-onset seizures (POS) (with or without secondary generalization) by expanding the approved age range from 12 years and above to 4 years and above, and for primary generalized tonic-clonic seizures (PGTCS) from 12 years and above to 7 years and above. more info >> |
|
|
Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020 |
| Results from LEAP-004 (Abstract #LBA44) and LEAP-005 (Abstract #LBA41) were accepted as late-breaking abstracts and are being presented in proffered paper presentations at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. more info >> |
|
| Friday, September 18, 2020 |
|
|
Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven (Eribulin) at ESMO Virtual Congress 2020 |
| Eisai Co., Ltd. has announced that the latest results from the cohort targeting patients with HER2-negative breast cancer in phase I clinical trial for the new liposomal formulation (E7389-LF) of the in-house discovered anti-cancer treatment Halaven were presented (abstract number: 346P) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. more info >> |
|
| Thursday, September 17, 2020 |
|
|
Eisai Establishes Pharma Sales Subsidiary in Vietnam |
| Eisai Co., Ltd. announced today that it has established a new pharmaceutical sales subsidiary in Ho Chi Minh City, the Socialist Republic of Viet Nam, which will be named Eisai Vietnam Co., Ltd., Eisai Vietnam is a wholly-owned subsidiary of Eisai. more info >> |
|
| Friday, September 11, 2020 |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2020 |
| Eisai Co., Ltd. announced today that a series of abstracts will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19 to 21, 2020. more info >> |
|
|
|
